Why Hyperlipidemia Matters Despite Non-Compensability
The VA does not assign a schedular rating to hyperlipidemia itself. The condition is treated as a laboratory finding, similar to elevated blood glucose or elevated blood pressure values that do not yet meet the threshold for a clinical diagnosis. A claim for direct service connection of hyperlipidemia alone will typically not produce a compensable rating.
The strategic value of establishing hyperlipidemia as secondary to a service-connected condition lies in what it enables downstream. Atherosclerotic cardiovascular disease is the leading cause of mortality and a major source of disability in adults. The pathophysiology runs through dyslipidemia: elevated LDL cholesterol drives endothelial dysfunction, foam cell formation, plaque development, and ultimately the clinical syndromes of coronary artery disease, peripheral artery disease, stroke, and erectile dysfunction. When dyslipidemia is established as secondary to PTSD, the chain to those downstream conditions becomes substantially easier to argue.
The PTSD-Dyslipidemia Mechanism
The PTSD-dyslipidemia relationship operates through several converging pathways.
Chronic Sympathetic Activation
PTSD produces sustained activation of the sympathetic nervous system, with elevated baseline norepinephrine and exaggerated catecholamine responses to triggers. Sympathetic activation increases hepatic VLDL secretion, reduces lipoprotein lipase activity in peripheral tissues, and impairs HDL-mediated reverse cholesterol transport. The cumulative effect is elevated triglycerides, elevated LDL, and reduced HDL — the classic dyslipidemia phenotype.
HPA-Axis Dysregulation
PTSD is associated with altered HPA-axis function, with paradoxical features (elevated CRH drive, blunted cortisol response in some studies, hypersensitive cortisol negative feedback in others). The net effect in many veterans is elevated cortisol exposure over time, particularly visceral cortisol effects. Cortisol promotes hepatic gluconeogenesis, lipolysis from adipose tissue with elevated free fatty acid flux to the liver, hepatic VLDL synthesis, and visceral adiposity. The visceral adiposity phenotype is itself a driver of insulin resistance, metabolic syndrome, and dyslipidemia.
Sleep Disruption
PTSD-related sleep disturbance (insomnia, nightmares, fragmented sleep) is an independent driver of metabolic dysfunction. Sleep deprivation increases insulin resistance, impairs glucose tolerance, elevates triglycerides, and reduces HDL. The metabolic effects of chronic sleep disruption are well documented in clinical and epidemiologic studies.
Behavioral Mediators
PTSD frequently produces reduced physical activity (avoidance, anhedonia, reduced motivation), increased intake of energy-dense comfort foods, and increased rates of tobacco and alcohol use. Each is an independent dyslipidemia driver, and the cumulative behavioral burden compounds the biologic mechanisms.
Medication-Induced Effects
Pharmacotherapy for PTSD frequently contributes directly to dyslipidemia:
- Atypical antipsychotics (quetiapine, olanzapine, risperidone, used off-label or augmenting for PTSD) cause weight gain and dyslipidemia, with olanzapine carrying the largest metabolic burden
- Mirtazapine causes weight gain and elevated lipids
- Some SSRIs (paroxetine notably) cause weight gain
- Topiramate (sometimes used adjunctively) can affect lipids
When the dyslipidemia is at least partly medication-induced, the opinion can be supported by reference to the specific agents prescribed and their documented metabolic profiles.
Population-Level Evidence
The PTSD-cardiovascular link has been documented in multiple veteran cohorts. Studies in the VA Million Veteran Program and other large veteran populations have shown elevated rates of coronary artery disease, hypertension, dyslipidemia, and diabetes among veterans with PTSD compared to non-PTSD veterans, persisting after adjustment for behavioral and demographic factors. The population evidence supports the individual-claim opinion.
What 38 CFR 3.310 Requires
Secondary service connection requires three elements.
Service-Connected Primary Condition
PTSD must already be service-connected, typically under DC 9411 in 38 CFR 4.130. The prior rating decision and treatment history should be in the record.
Current Hyperlipidemia Diagnosis
Hyperlipidemia is established by lipid panel showing elevated total cholesterol (greater than 200 mg/dL), elevated LDL (above the patient-specific target), elevated triglycerides (greater than 150 mg/dL), or reduced HDL (less than 40 mg/dL in men or less than 50 mg/dL in women), confirmed on repeat testing. The diagnosis is typically established by the primary care provider.
Medical Nexus Opinion
A medical professional must opine that the hyperlipidemia was caused by, the result of, or aggravated by the service-connected PTSD. The standard is at least as likely as not (50 percent probability or greater).
Aggravation Theory
When baseline dyslipidemia predated PTSD or arose from other factors but was worsened by PTSD-related mechanisms, 38 CFR 3.310(b) requires the opinion to identify baseline lipid values and current lipid values after aggravation.
Downstream Conditions That Are Rateable
The strategic payoff of the hyperlipidemia nexus is the downstream chained-secondary opportunities.
Coronary Artery Disease (DC 7005)
Rated 10/30/60/100 percent based on metabolic equivalents (METs) tolerated on cardiac stress testing, with consideration of left ventricular ejection fraction and presence of congestive heart failure. The chain runs PTSD to hyperlipidemia to atherosclerosis to coronary artery disease. Strong claims include cardiac catheterization, stress test, and echocardiography reports.
Peripheral Artery Disease (DC 7114)
Rated 20/40/60/100 percent based on claudication distance, ankle-brachial index, and presence of trophic changes or ulceration. The chain runs PTSD to hyperlipidemia to atherosclerosis to peripheral artery disease.
Stroke Residuals (DC 8008)
Minimum 100 percent for six months following a cerebrovascular accident, then residual-based. The chain runs PTSD to hyperlipidemia to atherosclerosis to ischemic stroke.
Erectile Dysfunction (DC 7522 plus SMC-K)
The vascular component of ED is well established and substantially mediated by atherosclerotic disease of penile and pelvic arteries. The chain runs PTSD to hyperlipidemia to vascular ED to the 0 percent DC 7522 rating plus the SMC-K loss-of-use entitlement under 38 USC 1114(k).
Carotid Artery Disease and Other Vascular Conditions
Symptomatic carotid stenosis, aortic disease, and renal artery disease are similarly downstream of dyslipidemia-driven atherosclerosis.
What the Nexus Letter Should Contain
A defensible nexus letter contains the following elements.
Reviewer Credentials
Identify the reviewing clinician (MD, DO, internist, cardiologist, psychiatrist with metabolic experience) and briefly state credentials relevant to PTSD metabolic complications.
Records Reviewed
Service treatment records, the prior rating decision establishing service connection for PTSD, post-service primary care and mental health records, serial lipid panels documenting the trajectory, weight and BMI trajectory, PTSD treatment history including psychiatric medications, sleep evaluation if applicable, any cardiovascular workup, and any documented atherosclerotic complications.
PTSD History
Summary of the PTSD diagnosis, severity, current rating, treatment history, and any documented behavioral or metabolic complications attributed to the condition or its treatment.
Hyperlipidemia History
Timeline of lipid panel values, weight changes, and the temporal relationship to the PTSD diagnosis and treatment. The closer the temporal alignment between PTSD onset (or treatment initiation) and the dyslipidemia development, the stronger the inference.
Nexus Opinion
An explicit at-least-as-likely-as-not opinion that the hyperlipidemia is caused by or aggravated by the service-connected PTSD.
Medical Reasoning
Rationale section articulating the sympathetic activation, HPA-axis, sleep, behavioral, and medication mechanisms in this veteran, with reference to the relevant clinical features (visceral adiposity, sleep disruption, specific medications). Reference the population-level evidence linking PTSD to cardiovascular and metabolic complications.
Downstream Mapping
When the veteran has any documented atherosclerotic complications (coronary disease, peripheral artery disease, prior TIA or stroke, ED), the opinion should explicitly map the chain from PTSD to hyperlipidemia to that downstream condition, supporting the chained-secondary claim.
Excluding Alternative Etiologies
A defensible nexus letter addresses other dyslipidemia contributors and articulates the relative contribution of PTSD.
Genetic and Familial Hyperlipidemia
Familial hypercholesterolemia and other inherited dyslipidemias produce dramatically elevated lipid values from a young age. Family history and the lipid magnitude should be addressed.
Diabetes
Diabetic dyslipidemia is its own well-recognized pattern (elevated triglycerides, reduced HDL, small dense LDL). When diabetes is present, the opinion should acknowledge it and articulate the additional PTSD contribution.
Hypothyroidism
Untreated hypothyroidism produces elevated LDL. TSH should be in the record.
Kidney Disease
Nephrotic syndrome and chronic kidney disease produce specific lipid patterns. Renal function should be addressed.
Diet and Lifestyle
Dietary fat intake, alcohol consumption, tobacco use, and physical activity level all affect lipids. The opinion should acknowledge these and articulate why PTSD-driven behavioral changes contribute.
Age and Sex
Lipid levels rise with age, and the patterns differ by sex. These are background factors, not alternative explanations.
Common Pitfalls
Several recurring issues weaken these claims.
Treating Hyperlipidemia as a Standalone Compensable Claim
The condition itself will not produce a schedular rating. The strategic value is the downstream chain. Letters that argue only for hyperlipidemia compensation typically fail.
Missing Downstream Mapping
When the veteran has documented atherosclerotic complications, omitting the explicit chained-secondary argument leaves substantial value on the table. The letter should map PTSD to hyperlipidemia to the downstream rateable condition.
Conclusory Mechanism Statement
A bare statement that "PTSD causes high cholesterol" without articulating the sympathetic, HPA, behavioral, and medication mechanisms is given low probative weight. The rationale section is essential.
Missing Medication Analysis
When the veteran is on metabolically active PTSD medications (atypical antipsychotics, mirtazapine), the medication contribution should be explicitly addressed. The medication pathway can carry the opinion in cases where the behavioral or HPA pathways are less well documented.
Wrong Legal Standard
Phrases like "possibly related" do not meet the at-least-as-likely-as-not threshold.
Frequently Asked Questions
Hyperlipidemia (high cholesterol or dyslipidemia) itself is generally not a compensable VA disability on its own. It is considered a laboratory finding rather than a rated condition. However, hyperlipidemia is medically important as the anchor diagnosis for downstream atherosclerotic conditions that ARE compensable: coronary artery disease, peripheral artery disease, stroke, and erectile dysfunction. Establishing hyperlipidemia as secondary to PTSD under 38 CFR 3.310 creates the foundation for chained-secondary claims of those rateable downstream conditions.
PTSD produces dyslipidemia through several converging mechanisms: chronic sympathetic nervous system activation increases hepatic VLDL secretion and reduces HDL clearance; HPA-axis dysregulation with elevated cortisol promotes lipolysis, hepatic gluconeogenesis, and visceral adiposity that drives the metabolic syndrome phenotype; behavioral mediators include sleep disruption (independent driver of metabolic dysfunction), reduced physical activity, and dietary changes; and medications used to treat PTSD (atypical antipsychotics, mirtazapine, some SSRIs) can directly elevate lipids. The PTSD-cardiovascular literature has documented elevated cardiovascular risk in veterans with PTSD independent of conventional risk factors.
The hyperlipidemia diagnosis is the entry point in a chained-secondary argument under 38 CFR 3.310 for downstream conditions that ARE compensable: coronary artery disease (DC 7005, 10/30/60/100 percent), peripheral artery disease (DC 7114, 20/40/60/100 percent), stroke residuals (DC 8008 minimum 100 percent for 6 months then residual-based), and erectile dysfunction (DC 7522 plus SMC-K loss-of-use). When PTSD is service-connected, the chain runs PTSD to hyperlipidemia to atherosclerosis to the specific ratable cardiovascular endpoint. Each link must be supported, but establishing hyperlipidemia secondary to PTSD is the foundational step.
Strong records include the prior rating decision establishing service connection for PTSD; serial lipid panels showing elevated total cholesterol, LDL, triglycerides, and/or reduced HDL; the temporal relationship between PTSD diagnosis and lipid abnormalities; PTSD treatment history including any psychiatric medications with metabolic side effects; weight and BMI trajectory; sleep disturbance documentation; and a medical opinion using at-least-as-likely-as-not language that articulates the sympathetic-HPA-behavioral-medication mechanism. When the goal is chained-secondary to a downstream cardiovascular endpoint, the evidence should also support the second link with imaging or functional testing of the cardiovascular system.
Need a Nexus Letter for Hyperlipidemia Secondary to PTSD?
Semper Solutus provides MD-authored medical opinions and nexus letters linking dyslipidemia to service-connected PTSD through the sympathetic-HPA-behavioral-medication mechanism under 38 CFR 3.310, with explicit downstream mapping to coronary artery disease, peripheral artery disease, stroke, and erectile dysfunction for chained-secondary claims. Schedule a free consultation to discuss your claim.
Book a Free Consultation